

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

APPOINTMENT OF DIRECTOR

APPOINTMENT OF DIRECTOR

The board of directors (the “**Board**”) of Sisram Medical Ltd (the “**Company**”) announced that, with effect from 20 August 2020, Ms. Rongli FENG (“**Ms. FENG**”) has been appointed as a non-executive director of the Company.

Ms. FENG, aged 44, has been the vice president of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the shares of which are listed both on The Stock Exchange of Hong Kong Limited (stock code: 2196) and the Shanghai Stock Exchange (stock code: 600196)) since April 2020, and the deputy chief human resources officer of Shanghai Fosun High Technology (Group) Co., Ltd.* (上海復星高科技(集團)有限公司) and the managing director of the human resources of Shanghai Fosun Venture Capital Investment Management Co., Ltd.* (上海復星創業投資管理有限公司) from July 2018 to April 2020. Ms. FENG is also a supervisor of Shanghai Henlius Biotech, Inc.* (上海復宏漢霖生物技術股份有限公司) (the shares of which are listed on The Stock Exchange of Hong Kong Limited (stock code: 2696)) and a non-executive director of Sinopharm Group Co. Ltd.* (國藥控股股份有限公司) (the shares of which are listed on The Stock Exchange of Hong Kong Limited (stock code: 1099)). Previously, Ms. FENG served as a human resources supervisor of Sealed Air Packaging (Shanghai) Co., Ltd.* (希悅爾包裝(上海)有限公司) from July 1996 to April 2000, a human resources manager of Grundfos Pumps (Shanghai) Co., Ltd.* (格蘭富水泵(上海)有限公司) from April 2000 to November 2002, the Asia-Pacific human resources manager of Emerson Electric (China) Investment Co., Ltd.* (艾默生電氣(中國)投資有限公司) from November 2002 to July 2006, the China human resources planning manager of Dow Chemical (China) Co., Ltd.* (陶氏化學(中國)有限公司) from August 2006 to November 2009, the director of human resources of Shanghai Roche Pharmaceutical Co., Ltd.* (上海羅氏製藥有限公司) from November 2009 to January 2015, and the senior director of human resources at F. Hoffmann-La Roche AG from February 2015 to July 2018. Ms. FENG graduated from Shanghai University in China with a major in microcomputer application in July 1996. In February 2002, she obtained a master’s degree in business administration from Columbia Southern University in the United States through long distance learning.

Save as disclosed above, Ms. FENG did not hold any directorship in listed public companies in the three years preceding the date of this announcement, nor does she has any relationship with any other director or senior management of the Company, or substantial or controlling shareholders of the Company.

As at the date of this announcement, Ms. FENG does not have any interest in the shares or underlying shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Ms. FENG has entered into a letter of appointment with the Company for a period commencing from 20 August 2020 and ending on 20 August 2023 in accordance with the articles of association of the Company. Pursuant to the articles of association of the Company, Ms. FENG will hold office as non-executive director of the Company until the forthcoming annual general meeting of the Company and will then stand for re-election at that meeting. Ms. FENG will not receive any emolument from the Company for acting as non-executive director of the Company.

Save as disclosed above, there is no other matter that needs to be brought to the attention of the Shareholders in connection with Ms. FENG's appointment and there is no other information that should be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to extend their warm welcome to Ms. FENG in joining the Board.

On Behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, 20 August 2020

As at the date of this announcement, the board of directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as executive directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Rongli FENG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *for identification purpose only*